Baidu
map

Diabetic Med:预先存在的糖尿病是肾移植后细胞排斥反应率升高的危险因素?

2017-08-31 MedSci MedSci原创

近日,国际杂志 《Diabetic Medicine》上在线发表一项关于预先存在的糖尿病是肾移植后细胞排斥反应率升高的危险因素的观察性队列研究。在一个很好的临床队列中,在现代免疫抑制的背景下,为了研究糖尿病患者是否有较高的肾移植排斥的风险。

近日,国际杂志 《Diabetic Medicine》上在线发表一项关于预先存在的糖尿病是肾移植后细胞排斥反应率升高的危险因素的观察性队列研究。在一个很好的临床队列中,在现代免疫抑制的背景下,为了研究糖尿病患者是否有较高的肾移植排斥的风险。

研究人员于2007年至2015年间,在一个中心进行了一项回顾性队列研究,包括所有肾脏同种异体移植受者,从患者的电子病历中将患者的临床,生物化学和组织病理学资料联系起来。对1140例肾移植受者进行了数据分析。移植后中位随访时间为4.4年,移植患者中有117例(10.2%)患有糖尿病。伴有糖尿病的肾脏同种异体移植受者与无糖尿病受者比较年龄较大(53vs 45岁;P<0.001),更可能为非白种人(41.0vs 26.4%;P=0.001)。伴有糖尿病肾脏同种异体移植受者与无糖尿病受者的细胞排斥风险较高(19.7vs12.4%; P = 0.024),但不是抗体介导的排斥反应(3.4vs 3.7%; P = 0.564)。移植器官功能和死亡检出风险在两组相似,但糖尿病肾脏同种异体移植受者与无糖尿病受者相比死亡风险高,总移植器官失败率高。在移植时不可改变的危险因素的cox回归模型中,发现糖尿病是细胞排斥的一个独立的危险因素(危险率为1.44595%CI 1.021.945P=0.042)

研究认为肾移植受者在移植时需要考虑他们的细胞排斥风险增加,但对于短期到中期同种异体移植的功能或存活没有任何不良影响。

原始出处:

S. Johal, F. Jackson-Spence, H. Gillott,et al. Pre-existing diabetes is a risk factor for increased rates of cellular rejection after kidney transplantation: an observational cohort study

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1760187, encodeId=49861e601876a, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Oct 17 09:34:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970517, encodeId=3cb019e05175b, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Sat Jan 13 15:34:00 CST 2018, time=2018-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808943, encodeId=a657180894351, content=<a href='/topic/show?id=8dcb826216c' target=_blank style='color:#2F92EE;'>#肾移植后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82621, encryptionId=8dcb826216c, topicName=肾移植后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aae2431, createdName=venlin, createdTime=Fri Sep 22 12:34:00 CST 2017, time=2017-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638016, encodeId=37c916380166c, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Jul 07 18:34:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262981, encodeId=90f81262981de, content=<a href='/topic/show?id=3c0f56643cd' target=_blank style='color:#2F92EE;'>#排斥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56643, encryptionId=3c0f56643cd, topicName=排斥)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Sat Sep 02 12:34:00 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532143, encodeId=11de1532143a1, content=<a href='/topic/show?id=54bb56644f5' target=_blank style='color:#2F92EE;'>#排斥反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56644, encryptionId=54bb56644f5, topicName=排斥反应)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Sep 02 12:34:00 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607990, encodeId=768a160e9904d, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Sep 02 12:34:00 CST 2017, time=2017-09-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1760187, encodeId=49861e601876a, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Oct 17 09:34:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970517, encodeId=3cb019e05175b, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Sat Jan 13 15:34:00 CST 2018, time=2018-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808943, encodeId=a657180894351, content=<a href='/topic/show?id=8dcb826216c' target=_blank style='color:#2F92EE;'>#肾移植后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82621, encryptionId=8dcb826216c, topicName=肾移植后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aae2431, createdName=venlin, createdTime=Fri Sep 22 12:34:00 CST 2017, time=2017-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638016, encodeId=37c916380166c, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Jul 07 18:34:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262981, encodeId=90f81262981de, content=<a href='/topic/show?id=3c0f56643cd' target=_blank style='color:#2F92EE;'>#排斥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56643, encryptionId=3c0f56643cd, topicName=排斥)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Sat Sep 02 12:34:00 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532143, encodeId=11de1532143a1, content=<a href='/topic/show?id=54bb56644f5' target=_blank style='color:#2F92EE;'>#排斥反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56644, encryptionId=54bb56644f5, topicName=排斥反应)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Sep 02 12:34:00 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607990, encodeId=768a160e9904d, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Sep 02 12:34:00 CST 2017, time=2017-09-02, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1760187, encodeId=49861e601876a, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Oct 17 09:34:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970517, encodeId=3cb019e05175b, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Sat Jan 13 15:34:00 CST 2018, time=2018-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808943, encodeId=a657180894351, content=<a href='/topic/show?id=8dcb826216c' target=_blank style='color:#2F92EE;'>#肾移植后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82621, encryptionId=8dcb826216c, topicName=肾移植后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aae2431, createdName=venlin, createdTime=Fri Sep 22 12:34:00 CST 2017, time=2017-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638016, encodeId=37c916380166c, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Jul 07 18:34:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262981, encodeId=90f81262981de, content=<a href='/topic/show?id=3c0f56643cd' target=_blank style='color:#2F92EE;'>#排斥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56643, encryptionId=3c0f56643cd, topicName=排斥)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Sat Sep 02 12:34:00 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532143, encodeId=11de1532143a1, content=<a href='/topic/show?id=54bb56644f5' target=_blank style='color:#2F92EE;'>#排斥反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56644, encryptionId=54bb56644f5, topicName=排斥反应)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Sep 02 12:34:00 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607990, encodeId=768a160e9904d, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Sep 02 12:34:00 CST 2017, time=2017-09-02, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1760187, encodeId=49861e601876a, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Oct 17 09:34:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970517, encodeId=3cb019e05175b, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Sat Jan 13 15:34:00 CST 2018, time=2018-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808943, encodeId=a657180894351, content=<a href='/topic/show?id=8dcb826216c' target=_blank style='color:#2F92EE;'>#肾移植后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82621, encryptionId=8dcb826216c, topicName=肾移植后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aae2431, createdName=venlin, createdTime=Fri Sep 22 12:34:00 CST 2017, time=2017-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638016, encodeId=37c916380166c, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Jul 07 18:34:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262981, encodeId=90f81262981de, content=<a href='/topic/show?id=3c0f56643cd' target=_blank style='color:#2F92EE;'>#排斥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56643, encryptionId=3c0f56643cd, topicName=排斥)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Sat Sep 02 12:34:00 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532143, encodeId=11de1532143a1, content=<a href='/topic/show?id=54bb56644f5' target=_blank style='color:#2F92EE;'>#排斥反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56644, encryptionId=54bb56644f5, topicName=排斥反应)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Sep 02 12:34:00 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607990, encodeId=768a160e9904d, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Sep 02 12:34:00 CST 2017, time=2017-09-02, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1760187, encodeId=49861e601876a, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Oct 17 09:34:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970517, encodeId=3cb019e05175b, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Sat Jan 13 15:34:00 CST 2018, time=2018-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808943, encodeId=a657180894351, content=<a href='/topic/show?id=8dcb826216c' target=_blank style='color:#2F92EE;'>#肾移植后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82621, encryptionId=8dcb826216c, topicName=肾移植后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aae2431, createdName=venlin, createdTime=Fri Sep 22 12:34:00 CST 2017, time=2017-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638016, encodeId=37c916380166c, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Jul 07 18:34:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262981, encodeId=90f81262981de, content=<a href='/topic/show?id=3c0f56643cd' target=_blank style='color:#2F92EE;'>#排斥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56643, encryptionId=3c0f56643cd, topicName=排斥)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Sat Sep 02 12:34:00 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532143, encodeId=11de1532143a1, content=<a href='/topic/show?id=54bb56644f5' target=_blank style='color:#2F92EE;'>#排斥反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56644, encryptionId=54bb56644f5, topicName=排斥反应)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Sep 02 12:34:00 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607990, encodeId=768a160e9904d, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Sep 02 12:34:00 CST 2017, time=2017-09-02, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1760187, encodeId=49861e601876a, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Oct 17 09:34:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970517, encodeId=3cb019e05175b, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Sat Jan 13 15:34:00 CST 2018, time=2018-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808943, encodeId=a657180894351, content=<a href='/topic/show?id=8dcb826216c' target=_blank style='color:#2F92EE;'>#肾移植后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82621, encryptionId=8dcb826216c, topicName=肾移植后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aae2431, createdName=venlin, createdTime=Fri Sep 22 12:34:00 CST 2017, time=2017-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638016, encodeId=37c916380166c, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Jul 07 18:34:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262981, encodeId=90f81262981de, content=<a href='/topic/show?id=3c0f56643cd' target=_blank style='color:#2F92EE;'>#排斥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56643, encryptionId=3c0f56643cd, topicName=排斥)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Sat Sep 02 12:34:00 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532143, encodeId=11de1532143a1, content=<a href='/topic/show?id=54bb56644f5' target=_blank style='color:#2F92EE;'>#排斥反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56644, encryptionId=54bb56644f5, topicName=排斥反应)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Sep 02 12:34:00 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607990, encodeId=768a160e9904d, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Sep 02 12:34:00 CST 2017, time=2017-09-02, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1760187, encodeId=49861e601876a, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Oct 17 09:34:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970517, encodeId=3cb019e05175b, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Sat Jan 13 15:34:00 CST 2018, time=2018-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808943, encodeId=a657180894351, content=<a href='/topic/show?id=8dcb826216c' target=_blank style='color:#2F92EE;'>#肾移植后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82621, encryptionId=8dcb826216c, topicName=肾移植后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aae2431, createdName=venlin, createdTime=Fri Sep 22 12:34:00 CST 2017, time=2017-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638016, encodeId=37c916380166c, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Jul 07 18:34:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262981, encodeId=90f81262981de, content=<a href='/topic/show?id=3c0f56643cd' target=_blank style='color:#2F92EE;'>#排斥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56643, encryptionId=3c0f56643cd, topicName=排斥)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Sat Sep 02 12:34:00 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532143, encodeId=11de1532143a1, content=<a href='/topic/show?id=54bb56644f5' target=_blank style='color:#2F92EE;'>#排斥反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56644, encryptionId=54bb56644f5, topicName=排斥反应)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Sep 02 12:34:00 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607990, encodeId=768a160e9904d, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Sep 02 12:34:00 CST 2017, time=2017-09-02, status=1, ipAttribution=)]

相关资讯

NEJM:利拉鲁肽可显著降低糖尿病肾病风险

研究表明,对于II糖尿病患者,服用利拉鲁肽可显著降低患者糖尿病肾病的发生和疾病进展

中国在全球率先开展干细胞教育治疗青少年发病1型糖尿病

8月30日下午,在中南大学湘雅二医院代谢内分泌科三病区病房里,来自美国纽约的1型糖尿病患儿Ivan正在接受干细胞教育治疗。作为全球首批接受该方法治疗的青少年发病1型糖尿病患者,经过前两个疗程的治疗后,Ivan病情明显好转。

J Periodontol:糖化胶原刺激牙龈成纤维细胞的分化

葡萄糖衍生的代谢物可能改变牙周膜中重要蛋白质的结构和生物学特性,如胶原蛋白。因此,胶原结合细胞可能改变其表型性状。虽然在牙周病变中可以检测到葡萄糖衍生物甲基乙二醛(MGO),胶质糖化对牙龈结缔组织生物学的精确影响尚未完全了解。本研究评估了MGO胶原糖化是否可能影响人类牙龈成纤维细胞(HGFs)的表型性质和重构能力。

Radiology:利用PET/MR进行全身成像在2型糖尿病的应用价值。

2型糖尿病原名叫成人发病型糖尿病,多在35~40岁之后发病,占糖尿病患者90%以上。2型糖尿病患者体内产生胰岛素的能力并非完全丧失,有的患者体内胰岛素甚至产生过多,但胰岛素的作用效果较差,因此患者体内的胰岛素是一种相对缺乏,可以通过某些口服药物刺激体内胰岛素的分泌。但到后期仍有一些病人需要使用胰岛素治疗。本研究旨在改善、评价和阐述利用全身成像序列评价胰岛素组织特异性介导18F- FDG的流入速率、

Mol Ther:二苯并氮杂草衍生物有望成为糖尿病新希望!

普渡大学的研究人员进行的一项研究表明,褐变的特殊脂肪可以系统性的改善新陈代谢,dibenzazepine纳米颗粒的潜在作用。

J NUTR BIOCHEM:可可化合物具有抗击糖尿病的潜力

糖尿病患者经常被警告不要吃太多巧克力。但现在杨百翰大学(BYU)的研究人员在可可中分离出一种化合物,可以通过推动增加β细胞分泌胰岛素的能力来帮助抗击 2 型糖尿病。2 型糖尿病发生发展的一个最主要的原因是胰岛β细胞功能的减退。

Baidu
map
Baidu
map
Baidu
map